SCHEMBL15564823

SCHEMBL15564823

CC(C)n1ncc(OCc2ccc(COCCO)cc2)c(Cl)c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BPTF Q12830 1/20 0.42
▸ ITGB1 P05556 1/20 0.35
▸ ITGA4 P13612 1/20 0.35
▸ ITGB7 P26010 1/20 0.35
▸ MAPK14 Q16539 5/20 0.35
▸ GAA P10253 1/20 0.34
▸ NR4A2 P43354 1/20 0.34
▸ PDE1C Q14123 2/20 0.33
▸ PDE9A O76083 1/20 0.33
▸ PDE1A P54750 1/20 0.33
▸ PDE1B Q01064 1/20 0.33
▸ EGLN1 Q9GZT9 1/20 0.33
▸ P2RX3 P56373 2/20 0.32
▸ KAT2B Q92831 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ HTR2C P28335 1/20 0.32
▸ HTT P42858 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15566104 0.91 BPTF (0.45) BPTFMAPK14GAAPDE1CPDE9A
SCHEMBL16901937 0.90 BPTF (0.43) BPTFMAPK14GAAPDE1CPDE9A
SCHEMBL15565769 0.88 BPTF (0.46) BPTFMAPK14GAAPDE1CPDE1A
SCHEMBL10854770 0.84 BPTF (0.46) BPTFMAPK14PDE1CPDE9APDE1A
SCHEMBL2318036 0.84 HTT (0.35) ITGB1ITGA4ITGB7MAPK14GAA
SCHEMBL15565563 0.83 BPTF (0.46) BPTFMAPK14GAAPDE1CPDE9A
SCHEMBL30863928 0.82 NR4A2 (0.37) BPTFMAPK14NR4A2EGLN1NPC1
SCHEMBL1629038 0.82 SMN1; SMN2 (0.45) ITGB1ITGA4ITGB7MAPK14GAA
SCHEMBL9239759 0.81 RAB9A (0.44) BPTFMAPK14NR4A2NPC1RAB9A
SCHEMBL15596673 0.81 RAB9A (0.46) BPTFP2RX3HTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2025-05-29 — — US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 — — US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 — — US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 — — US disclosed
CN-113754589-A Compositions, methods, and systems for synthesis and use of contrast agents 蓝瑟斯医学影像公司 2021-12-07 — — CN disclosed
CN-107311935-B Compositions, methods, and systems for synthesis and use of contrast agents 蓝瑟斯医学影像公司 2021-10-08 — — CN disclosed
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-07-23 — — US disclosed
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-07-23 — — US disclosed
EP-3653621-A1 APPARATUS FOR SYNTHESIZING THE IMAGING AGENT 4-CHLORO-2-(1,1-DIMETHYLETHYL)-5-[[4-[[2-(FLUORO-[18F])ETHOXY]METHYL]PHENYL]METHOXY]-3(2H)-PYRIDAZINONE (FLUORPIRIDAZ [18F]) Lantheus Medical Imaging, Inc. (US) 2020-05-20 — — EP disclosed
EP-3653621-A1 APPARATUS FOR SYNTHESIZING THE IMAGING AGENT 4-CHLORO-2-(1,1-DIMETHYLETHYL)-5-[[4-[[2-(FLUORO-[18F])ETHOXY]METHYL]PHENYL]METHOXY]-3(2H)-PYRIDAZINONE (FLUORPIRIDAZ [18F]) Lantheus Medical Imaging, Inc. (US) 2020-05-20 — — EP disclosed
US-20170151353-A9 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2017-06-01 — — US disclosed
US-9555138-B2 — — 2017-01-31 — — US disclosed
US-9555138-B2 — — 2017-01-31 — — US disclosed
US-9555138-B2 — — 2017-01-31 — — US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 — — US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 — — US disclosed
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2015-07-16 — — US disclosed
EP-2882719-A2 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS Lantheus Medical Imaging, Inc. (US) 2015-06-17 — — EP disclosed
WO-2014026079-A2 COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2014-02-13 — — WO disclosed
WO-2014026079-A2 COMPOSITIONS, METHODS, AND SYSTEMS OF THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2014-02-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150196672-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS TNNI3, FABP3, TNNT2 BPTF 4722/4885ITGB1 3251/4885ITGA4 2596/4885
US-20250170283-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 BPTF 4773/4885ITGB1 2970/4885ITGA4 2656/4885
US-20170151353-A9 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS TNNI3, FABP3, TNNT2 BPTF 4722/4885ITGB1 3251/4885ITGA4 2596/4885
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 BPTF 4773/4885ITGB1 2970/4885ITGA4 2656/4885
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents FABP3, TNNI3, TNNT2 BPTF 4773/4885ITGB1 2970/4885ITGA4 2656/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback